EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)

Results of the Latin American Pediatric Oncology Group (GALOP‐2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval‐Compressed Multiagent Chemotherapy

Lauro José Gregianin, Adriana Rose, Milena Villarroel, Maria Tereza Almeida, Laurice Siqueira, Carmen Salgado, Gildene Alves da Costa, Luis Castillo, Julie Francine Cerutti Santos Pestilho iD, Algemir Lunardi Brunetto, GALOP Latin American Pediatric Oncology Group Ewing Sarcoma Investigators

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31554 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Lauro José Gregianin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service of Pediatric Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Instituto do Câncer Infantil, Porto Alegre, RS, Brazil, Project Rafael Koff Accordi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GALOP investigators developed a prospective cooperative protocol for localized Ewing sarcoma (ES) incorporating interval‐compressed chemotherapy (VDC/IE, vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide). After completing conventional treatment, patients were randomized to 1 year of metronomic chemotherapy (vinblastine and cyclophosphamide).

Methods

Phase III randomized prospective trial. Induction consisted of six alternating cycles of VDC/IE every 14 days, followed by local control, and eight cycles of consolidation every 21 days. After consolidation, patients were randomized 1:1 to metronomic chemotherapy or stop treatment, balanced by age (>/< 14 years‐old), sex (M/F), site (pelvic/non‐pelvic), and size (>/< 8 cm). The results of randomization will be published elsewhere with longer follow‐up.

Results

Between 2011 and 2019, 315 patients (59.7% male, median age 11.0 years) were recruited across 34 centers in Argentina, Brazil, Chile, and Uruguay. The most frequent localizations were axial (45.1%), extremity (38.1%), and pelvic (16.8%). The median time interval between cycles was 19 and 22 days at induction and consolidation, respectively. There were no unexpected toxicity or toxic deaths related to interval compression. The overall response rate post‐induction was 81.6%. Local treatment with surgery (50.8%), radiotherapy (19.7%), or a combination (26%) was performed in 304 (96.5%) patients. With a median follow‐up of 50 months (range: 1.67–121.7), the 5‐year overall and event‐free survivals were 68.6% (SE: 0.030) and 63.7% (SE: 0.029), respectively.

Conclusion

Implementation of a multi‐institutional protocol with the strategy of interval‐compressed induction for ES in South America was feasible with favorable results. This success is attributed to rigorous protocol adherence, extensive educational efforts, and a strong emphasis on data quality maintenance, demonstrating a reproducible model for countries with similar resource limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsHumansMaleFemaleChildAdolescentProspective StudiesCyclophosphamideDoxorubicinVincristineEtoposideChild, PreschoolIfosfamideFollow-Up StudiesPrognosisLatin America

Stichwörter der Autor:innen

Ewing sarcomaclinical trialdose‐intensity

Substanzen

CyclophosphamideDoxorubicinVincristineEtoposideIfosfamide

Autor:innen und Institutionen

  • Service of Pediatric Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Department of Pediatrics, Universidade Federal do Rio Grande do Sul, Brazil.
  • Department of Hematology and Oncology, Hospital de Pediatría Dr J.P. Garrahan, Buenos Aires, Argentina.
  • Unidad de Oncologia, Hospital Dr. Luis Calvo Mackenna, Providencia, Chile.
  • Department of Pediatrics, Hospital das Clínicas de São Paulo-ITACI, São Paulo, Brazil.
  • Centro de Oncohematologia Pediatrica, Hospital Universitário Oswaldo Cruz, Recife, Brazil.

ORCID-Profile: Julie Francine Cerutti Santos Pestilho

Förderung

  • Instituto do Câncer Infantil, Porto Alegre, RS, Brazil
  • Project Rafael Koff Accordi

Zitieren

APA

Gregianin, L. J., Rose, A., Villarroel, M., Almeida, M. T., Siqueira, L., Salgado, C., da Costa, G. A., Castillo, L., Santos Pestilho, J. F. C., Brunetto, A. L., & GALOP Latin American Pediatric Oncology Group Ewing Sarcoma Investigators (2025). Results of the Latin American Pediatric Oncology Group (GALOP‐2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval‐Compressed Multiagent Chemotherapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31554

Vancouver

Gregianin LJ, Rose A, Villarroel M, Almeida MT, Siqueira L, Salgado C, et al. Results of the Latin American Pediatric Oncology Group (GALOP‐2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval‐Compressed Multiagent Chemotherapy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31554

BibTeX
@article{Gregianin2025,
  author = {Gregianin, Lauro José and Rose, Adriana and Villarroel, Milena and Almeida, Maria Tereza and Siqueira, Laurice and Salgado, Carmen and da Costa, Gildene Alves and Castillo, Luis and Santos Pestilho, Julie Francine Cerutti and Brunetto, Algemir Lunardi and GALOP Latin American Pediatric Oncology Group Ewing Sarcoma Investigators, GALOP Latin American Pediatric Oncology Group Ewing Sarcoma Investigators},
  title = {Results of the Latin American Pediatric Oncology Group (GALOP‐2011) Trial for Patients With Localized Ewing Sarcoma: A Multicentric Study of Interval‐Compressed Multiagent Chemotherapy},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31554}
}
Kostenlos starten →